Retuximab: A Flaw in the Grawl Study

In this study, they got greedy. Let's give retuximab to everyone, every single patient, regardless of CD20 expression. And then let's only measure CD20 expression in a handful of patients who have very, very high white blood cell counts. Can I play devil's advocate here? Sure. So when they did report on their subgroups, they didn't seem to find a difference on the expression of CD20. Whether you had high expression, low expression, the outcomes, the benefit or lack of benefit was really no different,. In the in the Grawl study? In this UK protocol? In the UK study.